Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bicara Therapeutics Inc. (BCAX)
:BCAX
BCAX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.10 - $28.09
Previous CloseN/A
Volume80.52K
Average Volume (3M)341.77K
Market Cap
$752.02M
Enterprise Value$865.50M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.53
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding54,415,620
10 Day Avg. Volume297,837
30 Day Avg. Volume341,767
Standard Deviation0.09
R-Squared0.04
Alpha-0.15
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap1.15
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-10.62
Forecast
1Y Price Target
$39.75Price Target Upside205.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Bicara Therapeutics Inc. News
---
Bulls Say, Bears Say
Bulls Say
Market PotentialBCAX shares are significantly undervalued based on ficerafusp alfa’s broad potential in EGFR+ solid tumors and strong balance sheet that should support development until approval.
Therapy InnovationFicerafusp alfa’s unique mechanism of action drives improvements over approved EGFR and PD-1 therapies.
Treatment EfficacyFicerafusp alfa has demonstrated deep and durable responses in head and neck squamous cell carcinoma, with response rates well above approved competitors.
Bears Say
Adverse Reactions46.4% of patients treated with the combination experienced a G3+ TRAE, with G3 ALT/AST elevations occurring in 14% and 7% of patients, respectively; 7.1% of patients discontinued treatment due to a TRAE.
Study EnrollmentEnrollment in the Ph1/1b study is currently on hold due to possible changes in the standard of care in an earlier line of therapy.
Trial LimitationsThe current research in squamous cancer of the anal canal is not included in the primary model, with focus remaining on other data updates.
---
Ownership Overview
37.38% Insiders
3.18% Mutual Funds
49.02% Other Institutional Investors
8.65% Public Companies and
Individual Investors
BCAX FAQ
What was Bicara Therapeutics Inc.’s price range in the past 12 months?
Bicara Therapeutics Inc. lowest stock price was $11.10 and its highest was $28.09 in the past 12 months.
What is Bicara Therapeutics Inc.’s market cap?
Bicara Therapeutics Inc.’s market cap is $752.02M.
When is Bicara Therapeutics Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Bicara Therapeutics Inc.’s earnings last quarter?
Bicara Therapeutics Inc. released its earnings results on Nov 12, 2024. The company reported -$1.6 earnings per share for the quarter, missing the consensus estimate of -$0.41 by -$1.19.
Is Bicara Therapeutics Inc. overvalued?
According to Wall Street analysts Bicara Therapeutics Inc.’s price is currently Undervalued.
Does Bicara Therapeutics Inc. pay dividends?
Bicara Therapeutics Inc. does not currently pay dividends.
What is Bicara Therapeutics Inc.’s EPS estimate?
Bicara Therapeutics Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bicara Therapeutics Inc. have?
Bicara Therapeutics Inc. has 54,415,620 shares outstanding.
What happened to Bicara Therapeutics Inc.’s price movement after its last earnings report?
Bicara Therapeutics Inc. reported an EPS of -$1.6 in its last earnings report, missing expectations of -$0.41. Following the earnings report the stock price went down -7.3%.
Which hedge fund is a major shareholder of Bicara Therapeutics Inc.?
Currently, no hedge funds are holding shares in BCAX
---
Bicara Therapeutics Inc. Stock Smart Score
Company Description
Bicara Therapeutics Inc.
Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Our lead program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, or HNSCC, where there remains a significant unmet need. We intend to initiate a pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab as a first-line therapy in recurrent/metastatic HNSCC excluding HPV-positive patients with oropharyngeal squamous cell carcinoma late in the fourth quarter of 2024 or early in the first quarter of 2025.
---
BCAX Stock 12 Month Forecast
Average Price Target
$39.75
▲(205.77% Upside)
Technical Analysis
Best Analysts Covering BCAX
1 Year
1 Year Success Rate
1/4 ratings generated profit
1 Year Average Return
-18.57%
reiterated a buy rating 12 days ago
Copying Stephen Willey's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -18.57% per trade.
---